Balaji Amines Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1cnw3df1zi9ilg4u9wq5vnnj.pdf

Key Takeaways


The Margin Reset: From Bonus to Baseline

D Ram Reddy: “I just want to clarify if you remember my earlier interviews I was telling that last 4 quarters, everybody in the country like Chemical Intermediate and Specialty Chemical API Pharma, we enjoyed some bonus period, bonus in the sense pre-COVID suppose before COVID if you have done some EBITDAs 20% - 22%, during this period we have done 39% - 40% EBITDAs and we cannot take that as a standard.”

Volume De-Growth: Pharma API and Raw Material Shocks


Subsidiary: Utilization Up, Raw Materials the Binding Constraint


New Plants: The FY24–FY25 Capacity Wave

D Ram Reddy: “We expect in the coming years these existing will grow with the 8% to 10% of the volumes and new plants immediately starting it should go first year about to 30% - 40% and the next year onwards it should go to 70% to 80%.”

Competitive Positioning and Pushback

D Ram Reddy: “If that is the case, my all Methyl, Ethyl everything is capital cost is absorbed, I am zero today, but still I am fighting with them.”

Governance and Leadership Changes


Guidance & Commitments

CommitmentSpecificsTimeline
Volume growthExisting products to grow 8–10% annually; new plants at 30–40% utilization year one, 70–80% year twoFY24 and beyond
Standalone volume targetDouble current volume to 180,000–190,000 tonsBy 2026
Margin improvement5–7% year-on-year improvement from current levelsFY24
N-Butylamines plant commissioningStart in H2 FY24; 40–50% utilization by year-endSeptember–October 2023
Methylamine plant commissioningPlant completionMarch 2024
Dimethyl ether plant commissioningCommissioning; exact date next quarterBy end of FY24
Acetonitrile plant (new technology)After DME; pilot plant done, going for main plantNext year (FY25)
DMAHCL and DMF plantsAfter ACN and DME; parallel executionAfter next year (FY26)
DMC and Propylene glycol utilizationReach 40–50% now; over 70–80% by year-endFY24
Subsidiary EDA capacity doublingDecision on doubling if demand warrantsCall in 2–3 months
Subsidiary land application~100 acres in Maharashtra; response expected1–2 weeks
CAPEX funding₹250–300 crores spent this year and next, all from internal accrualsFY24 and FY25
High-cost NMP raw material exhaustionLast high-cost inventory clearedFirst week of next month

Key Metrics

MetricQ4 FY23
Consolidated revenue₹477 cr, vs ₹785 cr in Q4 FY22
Standalone revenue₹351 cr, vs ₹625 cr in Q4 FY22
Consolidated EBITDA₹99 cr, vs ₹201 cr in Q4 FY22
Consolidated EBITDA margin21%, vs 26% in Q4 FY22
Standalone EBITDA margin17%, vs 21% in Q4 FY22
Consolidated PAT₹55 cr, vs ₹131 cr in Q4 FY22
Consolidated PAT margin12%, vs 17% in Q4 FY22
Consolidated diluted EPS₹14.63, vs ₹33.56 in Q4 FY22
Consolidated sales volume25,505 MT, vs 33,780 MT in Q4 FY22
Subsidiary sales volume4,916 MT, vs 4,903 MT in Q4 FY22
Subsidiary capacity utilization~72% in FY23, vs 56% in FY22
Standalone EBITDA margin target (sustainable)22%
Consolidated EBITDA margin target (sustainable)26-27%
FY24 volume growth outlook10%
FY24 margin improvement outlook5-7% improvement from current levels
FY24 CAPEX plan₹250-300 cr, funded through internal accruals